Top-News
Pharmazeutika USA

Takeda Pharma News

Aktie
WKN:  A1CWZF ISIN:  US8740602052 US-Symbol:  TAK
12,90 €
+0,40 €
+3,20%
13:21:31 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
3,14 Mrd.
Marktkapitalisierung *
38,67 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.01.2024

Takeda Pharma News

23.04.24 - PR Newswire
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire
22.04.24 - PR Newswire
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire
27.03.24 - PR Newswire
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire
27.03.24 - PR Newswire
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire
26.02.24 - PR Newswire
Championing Rare Voices on Rare Disease Day
Championing Rare Voices on Rare Disease Day Canada NewsWire
25.01.24 - PR Newswire
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation PR Newswire
17.11.23 - PR Newswire
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of ...
03.10.23 - PR Newswire
Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data
Takeda Launches New App to Help Healthcare Professionals Keep Pace with Important Clinical Trial Data Canada NewsWire
22.09.23 - PR Newswire
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 ...
12.09.23 - PR Newswire
Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
Patient-​led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge Canada NewsWire
21.12.22 - PR Newswire
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire
20.09.22 - PR Newswire
Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-Transplant Cytomegalovirus (CMV) infection
Health Canada approves Takeda's LIVTENCITY™ (maribavir) the First and Only Treatment for Adults with Post-​Transplant Cytomegalovirus (CMV) infection Canada NewsWire
14.09.22 - PR Newswire
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn's Disease PR Newswire
01.06.22 - PR Newswire
NICE recommends Revestive® ▼ (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)
NICE recommends Revestive® ▼ (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS) PR Newswire
16.06.21 - PR Newswire
Takeda Pharmaceuticals Marks its 240th Founding Anniversary
Takeda Pharmaceuticals Marks its 240th Founding Anniversary PR Newswire
16.06.21 - PR Newswire
Takeda Pharmaceuticals Marks its 240th Founding Anniversary
Takeda Pharmaceuticals Marks its 240th Founding Anniversary PR Newswire
09.06.21 - PR Newswire
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire
09.06.21 - PR Newswire
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community PR Newswire
01.03.21 - PR Newswire
The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases A five-year commitment from Takeda will help ...
08.02.21 - PR Newswire
Rute Fernandes Appointed General Manager of Takeda Canada
Rute Fernandes Appointed General Manager of Takeda Canada Canada NewsWire

Newssuche

Videos

08:55 Uhr -6,48%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »